Thursday, March 21, 2013
This week in
Publication and contact
Formulation of T cell
vaccines for cancer
Mouse studies suggest
saline formulations of T cell-targeted cancer vaccines could provide greater
antitumor activity than conventional adjuvant carriers. In a mouse model for
melanoma, subcutaneous injection with a tumor antigen vaccine formulated in
incomplete Freund's adjuvant (IFA), a widely used oil-based carrier, caused
accumulation of antigen-specific T cells at the injection site and elicited
lower antitumor activity than injection of a saline-based control formulation
of the same antigen. Mice receiving the saline-based formulation with an
adjuvant cocktail of IL-2,
receptor 7 (TLR7)
agonist and an antibody against CD40
had higher levels of tumor-infiltrating T cells than mice receiving an
IFA-based vaccine. Next steps include optimizing the vaccine formulation to
maximize dendritic cell uptake of the antigen and testing the formulation in
an investigator-led trial for melanoma.
Published online March 21, 2013
status not applicable
Hailemichael, Y. et al.
Nat. Med.; published online March 3, 2013;
Contact: Willem W. Overwijk, The University of Texas MD
Anderson Cancer Center, Houston, Texas
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]